My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 243

    1.

    Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.

    Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK.

    Diabetes Care. 2006 Nov;29(11):2361-4.PMID: 17065668 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

    Yurgin N, Secnik K, Lage MJ.

    Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

    3.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    4.

    The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.

    Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER.

    Diabet Med. 2006 Feb;23(2):128-33.PMID: 16433709 [PubMed - indexed for MEDLINE]Related articles

    5.

    Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

    Ann Intern Med. 2008 Oct 21;149(8):531-9.PMID: 18936501 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.

    Duckworth W, Marcelli M, Padden M, Kellick K, Duhancik T, Wilhardt M, Colgan K, Romie A.

    J Manag Care Pharm. 2003 May-Jun;9(3):256-62.PMID: 14613469 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.

    McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group.

    Diabetes Care. 2003 Jan;26(1):125-31.PMID: 12502668 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    9.

    Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

    Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

    Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.PMID: 18095238 [PubMed - indexed for MEDLINE]Related articles

    10.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    11.

    Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

    Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

    Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.PMID: 16800160 [PubMed - indexed for MEDLINE]Related articles

    12.

    A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

    Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

    Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

    13.

    Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.

    Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, Rawdaree P, Plengvidhya N, Leelawatana R, Bunnag P, Pratipanawatr T, Krittiyawong S, Suwanwalaikorn S, Deerochanawong C, Chetthakul T, Ngarmukos C, Komoltri C.

    J Med Assoc Thai. 2006 Aug;89 Suppl 1:S66-71.PMID: 17715836 [PubMed - indexed for MEDLINE]Related articles

    14.

    Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

    Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR.

    Diabetes Care. 2005 May;28(5):995-1000.PMID: 15855556 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Pharmacotherapy. 2007 Aug;27(8):1102-10.PMID: 17655510 [PubMed - indexed for MEDLINE]Related articles

    16.

    Weight change and duration of overweight and obesity in the incidence of type 2 diabetes.

    Wannamethee SG, Shaper AG.

    Diabetes Care. 1999 Aug;22(8):1266-72.PMID: 10480769 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

    Hollander P.

    Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.PMID: 17296341 [PubMed - indexed for MEDLINE]Related articles

    18.

    Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.

    Schiel R, Müller UA.

    Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):58-64. Epub 2007 Oct 31.PMID: 17973208 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    20.

    Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.

    Schiel R, Müller UA.

    Exp Clin Endocrinol Diabetes. 2007 Nov;115(10):627-33.PMID: 18058596 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity